Citigroup Maintains Buy on ResMed, Lowers Price Target to $340
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.